The risk factors of SARS-CoV-2 antibody level differences in healthcare workers post vaccination in Siloam hospitals: A nationwide multicenter study.

Widysanto, Allen; Prasetya, Ignatius Bima; Meriyanti, Tandry; Sungono, Veli; Setiawan, Diane Lukito; Gunawan, Edy; Adiputra, Bayu; Lorens, Jane Olivia; Santi, Theresia; Pradhana, Cindy Meidy Leony; Yusuf, Irawan; Gunawan, Catherine.

Widysanto A; Siloam Hospitals Lippo Village, Banten, Indonesia.
Prasetya IB; Faculty of Medicine, Pelita Harapan University, Banten, Indonesia.
Meriyanti T; Siloam Hospitals Lippo Village, Banten, Indonesia.
Sungono V; Faculty of Medicine, Pelita Harapan University, Banten, Indonesia.
Setiawan DL; Siloam Hospitals Lippo Village, Banten, Indonesia.
Gunawan E; Faculty of Medicine, Pelita Harapan University, Banten, Indonesia.
Adiputra B; Siloam Hospitals Surabaya, East Java, Indonesia.
Lorens JO; Clinical Research Department Siloam Hospitals Group, Banten, Indonesia.
Santi T; Clinical Research Department Siloam Hospitals Group, Banten, Indonesia.
Pradhana CML; Clinical Research Department Siloam Hospitals Group, Banten, Indonesia.
Yusuf I; Siloam Hospitals Lippo Cikarang, West Java, Indonesia.
Gunawan C; Faculty of Medicine, Pelita Harapan University, Banten, Indonesia.

Infect Med (Beijing) ; 1(4): 229-235, 2022 Dec.

Article en En | MEDLINE | ID: mdl-38013914

Palabras clave

Anti-SRBD, Anti-Spike-Receptor Binding Domain; Antibodies titer; COVID-19; COVID-19, Coronavirus Disease-19; FDA, Food and Drugs Administration; Immune response; MRIN, Mochtar Riady Institute for Nanotechnology; PCR, Polymerase Chain Reaction; S-RBD IgG; SARS-CoV-2, Severe Acute Respiratory Syndrome-Coronavirus-2; VE, Vaccine Efficacies; Vaccine; WHO, World Health Organization; mRNA, Messenger RiboNucleic Acid

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2022 Tipo del documento: Article